URGN(UroGen Pharma Ltd.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $48.04M | $64.36M | $82.71M | $90.40M | $109.79M |
| 毛利润 | $42.88M | $56.70M | $73.35M | $81.52M | $97.34M |
| 营业利润 | −$92.29M | −$79.04M | −$65.54M | −$96.78M | −$124.86M |
| 净利润 | −$110.82M | −$109.78M | −$102.24M | −$126.87M | −$153.49M |
| 经营现金流 | −$84.89M | −$87.56M | −$76.38M | −$96.77M | −$162.44M |
| 自由现金流 | −$85.64M | −$87.81M | −$76.57M | −$97.06M | −$162.73M |
| 摊薄每股收益 | $-4.96 | — | — | — | — |